Abstract:Successful drug discovery projects require control and optimization of compound properties related to pharmacokinetics, pharmacodynamics, and safety. While volume and chemotype coverage of public and corporate ADME-Tox (absorption, distribution, excretion, metabolism, and toxicity) databases are constantly growing, deep neural nets (DNN) emerged as transformative artificial intelligence technology to analyze those challenging data. Relevant features are automatically identified, while appropriate data can also be combined to multitask networks to evaluate hidden trends among multiple ADME-Tox parameters for implicitly correlated data sets. Here we describe a novel, fully industrialized approach to parametrize and optimize the setup, training, application, and visual interpretation of DNNs to model ADME-Tox data. Investigated properties include microsomal lability in different species, passive permeability in Caco-2/TC7 cells, and logD. Statistical models are developed using up to 50 000 compounds from public or corporate databases. Both the choice of DNN hyperparameters and the type and quantity of molecular descriptors were found to be important for successful DNN modeling. Alternate learning of multiple ADME-Tox properties, resulting in a multitask approach, performs statistically superior on most studied data sets in comparison to DNN single-task models and also provides a scalable method to predict ADME-Tox properties from heterogeneous data. For example, predictive quality using external validation sets was improved from R<sup>2</sup> of 0.6 to 0.7 comparing single-task and multitask DNN networks from human metabolic lability data. Besides statistical evaluation, a new visualization approach is introduced to interpret DNN models termed "response map", which is useful to detect local property gradients based on structure fragmentation and derivatization. This method is successfully applied to visualize fragmental contributions to guide further design in drug discovery programs, as illustrated by CRCX3 antagonists and renin inhibitors, respectively.

Prediction of human cytochrome P450 inhibition using a multi-task deep autoencoder neural network.

Prediction of Cytochrome P450 Inhibition Using a Deep Learning Approach and Substructure Pattern Recognition

ADMET Evaluation in Drug Discovery. 19. Reliable Prediction of Human Cytochrome P450 Inhibition Using Artificial Intelligence Approaches

DEEPCYPs: A Deep Learning Platform for Enhanced Cytochrome P450 Activity Prediction

Prediction of Cytochrome P450 Substrates Using the Explainable Multitask Deep Learning Models

Classification Of Cytochrome P450 1a2 Inhibitors And Noninhibitors Based On Deep Belief Network

Deep Learning Models Compared to Experimental Variability for the Prediction of CYP3A4 Time-Dependent Inhibition

Multitask CapsNet: an Imbalanced Data Deep Learning Method for Predicting Toxicants

Machine learning to predict metabolic drug interactions related to cytochrome P450 isozymes

A Unified GCNN Model for Predicting CYP450 Inhibitors by Using Graph Convolutional Neural Networks with Attention Mechanism

In Silico Prediction of CYP2C8 Inhibition with Machine-Learning Methods

Harnessing machine learning to predict cytochrome P450 inhibition through molecular properties

Attention-based Cross Domain Graph Neural Network for Prediction of Drug-Drug Interactions.

Predictive Multitask Deep Neural Network Models for ADME-Tox Properties: Learning from Large Data Sets

Evaluation of machine learning models for cytochrome P450 3A4, 2D6, and 2C9 inhibition

DeepP450: Predicting Human P450 Activities of Small Molecules by Integrating Pretrained Protein Language Model and Molecular Representation

Machine Learning Models to Predict Cytochrome P450 2B6 Inhibitors and Substrates

Development of In Silico Models for Predicting Potential Time-Dependent Inhibitors of Cytochrome P450 3A4

Classification of Cytochrome P450 Inhibitors and Noninhibitors Using Combined Classifiers.

Computational Prediction of the Isoform Specificity of Cytochrome P450 Substrates by an Improved Bayesian Method

Autoencoder-based Drug-Target Interaction Prediction by Preserving the Consistency of Chemical Properties and Functions of Drugs.